Patents by Inventor Anthony Gramolini
Anthony Gramolini has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10996229Abstract: Disclosed is a method for assessing heart failure in vitro including the steps of measuring in a sample the concentration of the marker IGFBP-7, of optionally measuring in the sample the concentration of one or more other marker(s) of heart failure, and of assessing heart failure by comparing the concentration determined in for IGFBP-7 and the concentration(s) determined for the optionally one or more other marker to the concentration of this marker or these markers as established in a reference population. Also disclosed are the use of IGFBP-7 as a marker protein in the assessment of heart failure, a marker combination comprising IGFBP-7 and a kit for measuring IGFBP-7.Type: GrantFiled: October 10, 2019Date of Patent: May 4, 2021Assignees: Roche Diagnostics Operations, Inc., The Governing Council of the University of TorontoInventors: Ursula-Henrike Wienhues-Thelen, Georg Hess, Hendrik Huedig, Herbert von der Eltz, Andrew Emili, Anthony Gramolini, Peter Liu, David MacLennan, Vincent Fong, Ruth Isserlin, Thomas Kislinger, Dirk Block
-
Publication number: 20200064359Abstract: Disclosed is a method for assessing heart failure in vitro including the steps of measuring in a sample the concentration of the marker IGFBP-7, of optionally measuring in the sample the concentration of one or more other marker(s) of heart failure, and of assessing heart failure by comparing the concentration determined in for IGFBP-7 and the concentration(s) determined for the optionally one or more other marker to the concentration of this marker or these markers as established in a reference population. Also disclosed are the use of IGFBP-7 as a marker protein in the assessment of heart failure, a marker combination comprising IGFBP-7 and a kit for measuring IGFBP-7.Type: ApplicationFiled: October 10, 2019Publication date: February 27, 2020Inventors: Ursula-Henrike Wienhues-Thelen, Georg Hess, Hendrik Huedig, Herbert von der Eltz, Andrew Emili, Anthony Gramolini, Peter Liu, David MacLennan, Vincent Fong, Ruth Isserlin, Thomas Kislinger, Dirk Block
-
Patent number: 10488422Abstract: Disclosed is a method for assessing heart failure in vitro including the steps of measuring in a sample the concentration of the marker IGFBP-7, of optionally measuring in the sample the concentration of one or more other marker(s) of heart failure, and of assessing heart failure by comparing the concentration determined in for IGFBP-7 and the concentration(s) determined for the optionally one or more other marker to the concentration of this marker or these markers as established in a reference population. Also disclosed are the use of IGFBP-7 as a marker protein in the assessment of heart failure, a marker combination comprising IGFBP-7 and a kit for measuring IGFBP-7.Type: GrantFiled: October 5, 2016Date of Patent: November 26, 2019Assignees: Roche Diagnostics Operations, Inc., The Governing Council of the University of TorontoInventors: Ursula-Henrike Wienhues-Thelen, Georg Hess, Hendrik Huedig, Herbert von der Eltz, Andrew Emili, Anthony Gramolini, Peter Liu, David MacLennan, Vincent Fong, Ruth Isserlin, Thomas Kislinger, Dirk Block
-
Publication number: 20170016918Abstract: Disclosed is a method for assessing heart failure in vitro including the steps of measuring in a sample the concentration of the marker IGFBP-7, of optionally measuring in the sample the concentration of one or more other marker(s) of heart failure, and of assessing heart failure by comparing the concentration determined in for IGFBP-7 and the concentration(s) determined for the optionally one or more other marker to the concentration of this marker or these markers as established in a reference population. Also disclosed are the use of IGFBP-7 as a marker protein in the assessment of heart failure, a marker combination comprising IGFBP-7 and a kit for measuring IGFBP-7.Type: ApplicationFiled: October 5, 2016Publication date: January 19, 2017Inventors: Ursula-Henrike Wienhues-Thelen, Georg Hess, Hendrik Huedig, Herbert von der Eltz, Andrew Emili, Anthony Gramolini, Peter Liu, David MacLennan, Vincent Fong, Ruth Isserlin, Thomas Kislinger, Dirk Block
-
Publication number: 20160146836Abstract: The invention relates to a method for assessing heart failure in vitro comprising the steps of measuring in a sample the concentration of the marker CRYAB, of optionally measuring in the sample the concentration of one or more other marker(s) of heart failure selected from the group consisting of a natriuretic peptide marker, a cardiac troponin marker, and a marker of inflammation, and of assessing heart failure by comparing the concentration determined in for CRYAB and the concentration(s) determined for the optionally one or more other marker to the concentration of this marker or these markers as established in a reference population. Also disclosed are the use of CRYAB as a marker protein in the assessment of heart failure, a marker combination comprising CRYAB and a kit for measuring CRYAB.Type: ApplicationFiled: January 27, 2016Publication date: May 26, 2016Inventors: Ursula-Henrike Wienhues-Thelen, Georg Hess, Dirk Block, Hendrik Huedig, Andrew Emili, Anthony Gramolini, Peter Liu, David MacLennan, Sara Arab
-
Patent number: 9267954Abstract: The invention relates to a method for assessing heart failure in vitro comprising the steps of measuring in a sample the concentration of the marker SLIM-1, of optionally measuring in the sample the concentration of one or more other marker(s) of heart failure, and of assessing heart failure by comparing the concentration determined in for SLIM-1 and the concentration(s) determined for the optionally one or more other marker to the concentration of this marker or these markers as established in a reference population. Also disclosed are the use of SLIM-1 as a marker protein in the assessment of heart failure, a marker combination comprising SLIM-1 and a kit for measuring SLIM-1.Type: GrantFiled: September 4, 2009Date of Patent: February 23, 2016Assignee: The Governing Council of the University of TorontoInventors: Ursula-Henrike Wienhues-Thelen, Georg Hess, Hendrik Huedig, Herbert von der Eltz, Andrew Emili, Anthony Gramolini, Peter Liu, David MacLennan, Vincent Fong, Ruth Isserlin, Thomas Kislinger, Dirk Block
-
Publication number: 20150293122Abstract: The invention relates to a method for assessing heart failure in vitro comprising the steps of measuring in a sample the concentration of the marker IGFBP-7, of optionally measuring in the sample the concentration of one or more other marker(s) of heart failure, and of assessing heart failure by comparing the concentration determined in for IGFBP-7 and the concentration(s) determined for the optionally one or more other marker to the concentration of this marker or these markers as established in a reference population. Also disclosed are the use of IGFBP-7 as a marker protein in the assessment of heart failure, a marker combination comprising IGFBP-7 and a kit for measuring IGFBP-7.Type: ApplicationFiled: November 13, 2014Publication date: October 15, 2015Inventors: Ursula-Henrike Wienhues-Thelen, Georg Hess, Hendrik Huedig, Herbert von der Eltz, Andrew Emili, Anthony Gramolini, Peter Liu, David MacLennan, Vincent Fong, Ruth Isserlin, Thomas Kislinger, Dirk Block
-
Publication number: 20140193845Abstract: Disclosed is a method for assessing heart failure in vitro including the steps of measuring in a sample the concentration of the marker SFRP-3, of optionally measuring in the sample the concentration of one or more other marker(s) of heart failure, and of assessing heart failure by comparing the concentration determined in for SFRP-3 and the concentration(s) determined for the optionally one or more other marker to the concentration of this marker or these markers as established in a reference population. Also disclosed are the use of SFRP-3 as a marker protein in the assessment of heart failure, a marker combination comprising SFRP-3 and a kit for measuring SFRP-3.Type: ApplicationFiled: February 14, 2014Publication date: July 10, 2014Applicants: The Governing Council of the University of Toronto, Roche Diagnostics Operations, Inc.Inventors: Ursula-Henrike Wienhues-Thelen, Sara Arab, Dirk Block, Andrew Emili, Anthony Gramolini, Georg Hess, Hendrik Huedig, Peter Liu, David MacLennan
-
Patent number: 8691587Abstract: Disclosed is a method for assessing heart failure in vitro including the steps of measuring in a sample the concentration of the marker SFRP-3, of optionally measuring in the sample the concentration of one or more other marker(s) of heart failure, and of assessing heart failure by comparing the concentration determined in for SFRP-3 and the concentration(s) determined for the optionally one or more other marker to the concentration of this marker or these markers as established in a reference population. Also disclosed are the use of SFRP-3 as a marker protein in the assessment of heart failure, a marker combination comprising SFRP-3 and a kit for measuring SFRP-3.Type: GrantFiled: October 11, 2010Date of Patent: April 8, 2014Assignee: Roche Diagnostics Operations, Inc.Inventors: Ursula-Henrike Wienhues-Thelen, Sara Arab, Dirk Block, Andrew Emili, Anthony Gramolini, Georg Hess, Hendrik Heudig, Peter Liu, David MacLennan
-
Publication number: 20110165591Abstract: The invention relates to a method for assessing heart failure in vitro and involves the steps of measuring in a sample the concentration of the marker biglycan, of optionally measuring in the sample the concentration of one or more other marker(s) of heart failure, and of assessing heart failure by comparing the concentration determined in for biglycan and the concentration(s) determined for the optionally one or more other marker to the concentration of this marker or these markers as established in a reference population. Also disclosed are the use of biglycan as a marker protein in the assessment of heart failure, a marker combination comprising biglycan and a kit for measuring biglycan.Type: ApplicationFiled: March 15, 2011Publication date: July 7, 2011Inventors: Ursula-Henrike Wienhues-Thelen, Sara Arab, Dirk Block, Andrew Emili, Anthony Gramolini, Georg Hess, Hendrik Huedig, Peter Liu, David MacLennan
-
Publication number: 20110027819Abstract: Disclosed is a method for assessing heart failure in vitro including the steps of measuring in a sample the concentration of the marker SFRP-3, of optionally measuring in the sample the concentration of one or more other marker(s) of heart failure, and of assessing heart failure by comparing the concentration determined in for SFRP-3 and the concentration(s) determined for the optionally one or more other marker to the concentration of this marker or these markers as established in a reference population. Also disclosed are the use of SFRP-3 as a marker protein in the assessment of heart failure, a marker combination comprising SFRP-3 and a kit for measuring SFRP-3.Type: ApplicationFiled: October 11, 2010Publication date: February 3, 2011Inventors: Ursula-Henrike Wienhues-Thelen, Sara Arab, Dirk Block, Andrew Emili, Anthony Gramolini, Georg Hess, Hendrik Heudig, Peter Liu, David MacLennan
-
Publication number: 20100285492Abstract: The invention relates to a method for assessing heart failure in vitro comprising the steps of measuring in a sample the concentration of the marker SLIM-1, of optionally measuring in the sample the concentration of one or more other marker(s) of heart failure, and of assessing heart failure by comparing the concentration determined in for SLIM-1 and the concentration(s) determined for the optionally one or more other marker to the concentration of this marker or these markers as established in a reference population. Also disclosed are the use of SLIM-1 as a marker protein in the assessment of heart failure, a marker combination comprising SLIM-1 and a kit for measuring SLIM-1.Type: ApplicationFiled: September 4, 2009Publication date: November 11, 2010Inventors: Ursula-Henrike Wienhues-Thelen, Georg Hess, Hendrik Huedig, Herbert von der Eltz, Andrew Emili, Anthony Gramolini, Peter Liu, David MacLennan, Vincent Fong, Ruth Isserlin, Thomas Kislinger, Dirk Block
-
Publication number: 20100285491Abstract: The invention relates to a method for assessing heart failure in vitro comprising the steps of measuring in a sample the concentration of the marker IGFBP-7, of optionally measuring in the sample the concentration of one or more other marker(s) of heart failure, and of assessing heart failure by comparing the concentration determined in for IGFBP-7 and the concentration(s) determined for the optionally one or more other marker to the concentration of this marker or these markers as established in a reference population. Also disclosed are the use of IGFBP-7 as a marker protein in the assessment of heart failure, a marker combination comprising IGFBP-7 and a kit for measuring IGFBP-7.Type: ApplicationFiled: July 16, 2009Publication date: November 11, 2010Inventors: Ursula-Henrike Wienhues-Thelen, Georg Hess, Hendrik Huedig, Herbert von der Eltz, Andrew Emili, Anthony Gramolini, Peter Liu, David MacLennan, Vincent Fong, Ruth Isserlin, Thomas Kislinger, Dirk Block